RMB 22 billion in capital floods in! Innovative drugs benefit from policy dividends as the wave of business development in the industry continues to heat up.

The innovative drug sector has received another positive policy signal.

Securities Times ChinaSep 5 13:41

Day One of the 2026 National Reimbursement Drug List Negotiations: Representatives from Multiple Companies Display Visible Joy as Traditional Chinese Medicine and Chronic Disease Drugs Take Center Stage

The annual national medical insurance catalog negotiations have once again entered the stage of on-site bargaining.

cls.cnSep 5 18:02

HK Stocks Move: Sihuan Pharmaceutical (00460) Rises Nearly 4% in Morning Session as Xuanzhu Biopharma and INNOBIC Reach Commercialization Agreement for Pyroxasulfone in Thailand

Shares of Sihuan Pharmaceutical (00460) rose nearly 4% in morning trading. As of press time, the stock was up 3.92% at HK$0.795, with turnover reaching HK$9.813 million.

Zhitong FinanceSep 4 11:52

Express News | National Healthcare Security Administration: More innovative drugs expected to be included in medical insurance reimbursement

Li Tao, Deputy Director of the National Healthcare Security Administration, stated at a press conference held by the State Council Information Office on the 4th, themed "Kickstarting the 15th Five-Year Plan," that the basic medical insurance drug catalog will continue to be adjusted annually. More innovative drugs for major diseases and key areas—including cancer, chronic diseases, rare diseases, and pediatric conditions—that meet eligibility criteria will be included in medical insurance reimbursement. Efforts will also be made to promote the national unification of reimbursement catalogs for medical service items and medical consumables, thereby further narrowing policy disparities across regions. (Xinhua News Agency)

BreakingsSep 4 10:19

Four Rings Medicine (00460.HK): Xuanzhu Biology and INNOBIC Reach Commercialization Agreement for Piroxiciclib in the Thai Market

Gelonghui, September 3 | Four Rings Medicine (00460.HK) announced that its non-wholly owned subsidiary, Xuanzhu Biotechnology Co., Ltd. (“Xuanzhu Biotech”, stock code: 02575.HK), recently signed a tripartite commercial agreement with Thai pharmaceutical company Innobic (Asia) Co., Ltd. (“Innobic (Asia)”) and Zao An International Trading Co., Ltd. (“Zao An International”) regarding Xuanzhu Biotech’s pyrotinib tablets (the “Target Product”). The agreement is valid until June 2036.

Gelonghui FinanceSep 3 17:21

Sihuan Pharmaceutical Grants 116 Million Performance-Based Share Awards

TipRanksSep 1 21:23